read this

Found this article on Analytical's Webb site today under RECENT ANNOUNCEMENTS-Appendix 4E 25 August 2011
Preliminary Final Report by Dr Michael Monsour chairman who is also a director of CBIO-----

AFTER BALANCE DATE EVENTS
On the 1st August CBio Ltd submitted to the ASX an announcement CBIO ANNOUNCES HEADLINE
RESULTS OF PHASE IIA RHEUMATOID ARTHRITIS CLINICAL TRIAL This announcement was
framed in technical language. We understand from our reading of this announcement that the trial was
very positive, yet the overall wording, to say the least, was negative. The impact on the share price was
a fall from 68 cents to 28.5 cents per share. Analytica Ltd holds 1,000,000 shares, so experienced a
reduction in value of $395,000. At the date of this announcement the price has not recovered. The
price at the close of 30th June 2011 was 63 cents.